134 related articles for article (PubMed ID: 34609269)
1. Molecular basis for reduced cleavage activity and drug resistance in D30N HIV-1 protease.
Bihani SC; Gupta GD; Hosur MV
J Biomol Struct Dyn; 2022; 40(23):13127-13135. PubMed ID: 34609269
[TBL] [Abstract][Full Text] [Related]
2. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
3. Structural Basis of Why Nelfinavir-Resistant D30N Mutant of HIV-1 Protease Remains Susceptible to Saquinavir.
Prashar V; Bihani SC; Ferrer JL; Hosur MV
Chem Biol Drug Des; 2015 Sep; 86(3):302-8. PubMed ID: 25487655
[TBL] [Abstract][Full Text] [Related]
4. Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.
Soares RO; Batista PR; Costa MG; Dardenne LE; Pascutti PG; Soares MA
J Mol Graph Model; 2010 Sep; 29(2):137-47. PubMed ID: 20541446
[TBL] [Abstract][Full Text] [Related]
5. Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART.
Røge BT; Katzenstein TL; Nielsen HL; Gerstoft J
HIV Med; 2003 Jan; 4(1):38-47. PubMed ID: 12534958
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 protease-substrate coevolution in nelfinavir resistance.
Kolli M; Ozen A; Kurt-Yilmaz N; Schiffer CA
J Virol; 2014 Jul; 88(13):7145-54. PubMed ID: 24719428
[TBL] [Abstract][Full Text] [Related]
7. Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.
Clemente JC; Hemrajani R; Blum LE; Goodenow MM; Dunn BM
Biochemistry; 2003 Dec; 42(51):15029-35. PubMed ID: 14690411
[TBL] [Abstract][Full Text] [Related]
8. N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure.
Mitsuya Y; Winters MA; Fessel WJ; Rhee SY; Hurley L; Horberg M; Schiffer CA; Zolopa AR; Shafer RW
AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1300-5. PubMed ID: 17209774
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts.
Clotet B; Ruiz L; Martinez-Picado J; Negredo E; Hill A; Popescu M
HIV Clin Trials; 2002; 3(4):316-23. PubMed ID: 12187506
[TBL] [Abstract][Full Text] [Related]
10. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
[TBL] [Abstract][Full Text] [Related]
11. New insights into the in silico prediction of HIV protease resistance to nelfinavir.
Antunes DA; Rigo MM; Sinigaglia M; de Medeiros RM; Junqueira DM; Almeida SE; Vieira GF
PLoS One; 2014; 9(1):e87520. PubMed ID: 24498124
[TBL] [Abstract][Full Text] [Related]
12. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.
Grossman Z; Paxinos EE; Averbuch D; Maayan S; Parkin NT; Engelhard D; Lorber M; Istomin V; Shaked Y; Mendelson E; Ram D; Petropoulos CJ; Schapiro JM
Antimicrob Agents Chemother; 2004 Jun; 48(6):2159-65. PubMed ID: 15155216
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment.
Tupinambás U; Aleixo A; Greco D
Braz J Infect Dis; 2005 Aug; 9(4):324-9. PubMed ID: 16270125
[TBL] [Abstract][Full Text] [Related]
14. [HIV genotypic mutation selectively induced by the protease inhibitor nelfinavir at codon 30. Case series and consequences for antiretroviral management].
Manfredi R; Calza L
Infez Med; 2002 Sep; 10(3):151-6. PubMed ID: 12704265
[TBL] [Abstract][Full Text] [Related]
15. Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases.
Ode H; Ota M; Neya S; Hata M; Sugiura W; Hoshino T
J Phys Chem B; 2005 Jan; 109(1):565-74. PubMed ID: 16851048
[TBL] [Abstract][Full Text] [Related]
16. Parameters driving the selection of nelfinavir-resistant human immunodeficiency virus type 1 variants.
Perrin V; Mammano F
J Virol; 2003 Sep; 77(18):10172-5. PubMed ID: 12941931
[TBL] [Abstract][Full Text] [Related]
17. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
[TBL] [Abstract][Full Text] [Related]
18. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.
Patick AK; Duran M; Cao Y; Shugarts D; Keller MR; Mazabel E; Knowles M; Chapman S; Kuritzkes DR; Markowitz M
Antimicrob Agents Chemother; 1998 Oct; 42(10):2637-44. PubMed ID: 9756769
[TBL] [Abstract][Full Text] [Related]
19. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.
Martinez-Picado J; Savara AV; Sutton L; D'Aquila RT
J Virol; 1999 May; 73(5):3744-52. PubMed ID: 10196268
[TBL] [Abstract][Full Text] [Related]
20. Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate.
Kolli M; Lastere S; Schiffer CA
Virology; 2006 Apr; 347(2):405-9. PubMed ID: 16430939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
